Research Articles
Pharmacokinetics and Bioavailability of Cimetidine in Humans

https://doi.org/10.1002/jps.2600690408Get rights and content

Abstract

Cimetidine given orally without food after an overnight fast produces a blood concentration curve with a pronounced second peak that does not appear after parenteral administration or when the drug is taken with food. The following interpretation of this kinetic phenomenon is proposed: 1. The drug cumulates in a tissue or organ that is well perfused in the first-pass transfer. 2. The hepatic parenchymal tissue and the bile phase are the most likely storage areas. 3. The high capacity of the cumulation may be due to the formation of conjugates or other modifications of the drug with a pronounced affinity for the hepaticbiliary system. 4. The rate of cumulation is much higher in the first-pass transfer than from the systemic circulation, possibly due to the difference in the drug concentrations and the conjugation rate. 5. The cumulation appears to occur by a competitive process. 6. Absorbed elements of food seem to compete in this process. 7. The second peak apparently is the result of a rapid release of drug and bioreversible drug compounds from the hepatic-biliary system with subsequent reabsorption. 8. This release may occur spontaneously but appears to be triggered by food intake. A pharmacokinetic model constructed according to this interpretation showed good agreement with data from oral, intravenous, and intramuscular administration. The special problems associated with the evaluation of bioavailability in the presence of reabsorption are discussed.

References (29)

  • WalkensteinS.S. et al.

    Gastroenterology

    (1978)
  • PedersenP.Veng et al.

    J. Pharm. Sci.

    (1980)
  • PedersenP.Veng

    J. Pharm. Sci.

    (1978)
  • QuickA.J.

    J. Biol. Chem.

    (1932)
  • BodemarG. et al.

    Br. J. Clin. Pharmacol.

    (1979)
  • BurlandW.L. et al.

    Br. J. Clin. Pharmacol.

    (1975)
  • SpenceR.W. et al.

    Digestion

    (1976)
  • SpenceR.W. et al.

    Proceedings of the Second International Symposium on Histamine H2-Receptor Antagonists

    (1977)
  • GriffithsR. et al.

    Proceedings of the Second International Symposium on Histamine H2-receptor Antagonists

    (1977)
  • HennR.H. et al.

    N. Engl. J. Med.

    (1975)
  • BodemarG. et al.

    Proceedings of the Second International Symposium on Histamine H2-receptor Antagonists

    (1977)
  • BoydenE.A.

    Anat. Rec.

    (1928)
  • Anat. Rec.

    (1928)
  • ThornC.D.

    Bull. Math. Biophys.

    (1972)
  • Cited by (123)

    • Effect of liver disease on pharmacokinetics

      2021, Atkinson's Principles of Clinical Pharmacology
    • Old wine in new bottles: Drug repurposing in oncology

      2020, European Journal of Pharmacology
    • Investigation of a nanosuspension stabilized by Soluplus<sup>®</sup> to improve bioavailability

      2014, International Journal of Pharmaceutics
      Citation Excerpt :

      Double absorption peaks were present in the mean plasma concentration–time curves of Antara® pellets and nanosuspensions. Previously, several hypotheses had been put forward for the phenomenon of double peaks in absorption curves, such as region-dependent variations in absorption (Piyapolrungroj et al., 2000), gastrointestinal motility (Oberle and Amidon, 1987), intestinal bacterial reconversion of biliary metabolites and enterohepatic recirculation (Pedersen, 1981; Pedersen and Miller, 1980). According to the study of Lili Zhang (Zhang et al., 2010), the phenomenon may be caused by the different absorption sites of FBT in GI tract.

    • Effect of Liver Disease on Pharmacokinetics

      2012, Principles of Clinical Pharmacology, Third Edition
    View all citing articles on Scopus
    View full text